将基因组学整合到神经肿瘤学临床试验与实践中。

Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice.

作者信息

Galanis Evanthia, Nassiri Farhad, Coy Shannon, Nejad Romina, Zadeh Gelareh, Santagata Sandro

机构信息

From the Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; MacFeeters Hamilton Centre for Neuro-Oncology Research, University of Toronto, Toronto, ON, Canada; Ludwig Center at Harvard, Department of Pathology, Boston Children's Hospital, and Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

出版信息

Am Soc Clin Oncol Educ Book. 2018 May 23;38:148-157. doi: 10.1200/EDBK_200989.

DOI:10.1200/EDBK_200989

PMID:30231374

Abstract

Important advances in our understanding of the molecular biology of brain tumors have resulted in a rapid evolution in the taxonomy of central nervous system (CNS) tumors, which culminated in the revised 2016 World Health Organization classification of CNS tumors that incorporates an integrated molecular/histologic diagnostic approach. Our expanding understanding of brain tumor genomics and molecular evolution during the disease course has started to impact clinical management. Furthermore, incorporation of genomic information in ongoing and planned neuro-oncology clinical trials is expected to lead to improved outcomes and result in personalized treatment options for patients with CNS malignancies.

摘要

我们对脑肿瘤分子生物学的理解取得了重要进展，这导致中枢神经系统（CNS）肿瘤的分类迅速演变，最终形成了2016年修订的世界卫生组织中枢神经系统肿瘤分类，该分类纳入了综合分子/组织学诊断方法。我们对疾病过程中脑肿瘤基因组学和分子进化的不断深入理解已开始影响临床管理。此外，将基因组信息纳入正在进行和计划中的神经肿瘤学临床试验有望带来更好的治疗结果，并为中枢神经系统恶性肿瘤患者带来个性化的治疗选择。